Here are the 10-K annual reports from X4 Pharmaceuticals, Inc. (XFOR) in our archive since June 2025, newest first, and each one links through to the document itself with the summary and the scores our analysis gives it.
A 10-K covers the audited annual report, with the full financial statements, so if you follow XFOR and want that one kind of document rather than the whole filing history, this is the page to keep. The company's other filings, of every form, are on the full XFOR filings page.
X4 Pharmaceuticals outlines a major transition in its annual report for the year ended December 31, 2025. The company focuses on rare hematology diseases, led by XOLREMDI (mavorixafor), which has accelerated FDA approval for WHIM syndrome and Fast Track status in chronic neutropenia.
X4 is running the pivotal 52‑week Phase 3 4WARD trial in chronic neutropenia, targeting 176 patients and aiming for top-line data in the second half of 2027. In August 2025, the company overhauled leadership and executed restructurings that cut headcount by about 65% to align around this program.
Funding was strengthened through an August 2025 PIPE that raised net $81.0 million and a fourth-quarter public offering with net proceeds of $145.6 million, leaving $253.0 million in cash, cash equivalents and marketable securities as of December 31, 2025. X4 also signed regional commercialization deals, including a €28.5 million upfront license with Norgine and distribution agreements in Europe, MENA, and China, while a positive EMA opinion for WHIM is under review by the European Commission.